Last updated on July 2018

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort Turbuhaler in Patients With Chronic Obstructive Pulmonary Disease ( COPD)


Brief description of study

The purpose of this study is to demonstrate the superiority of CHF 5993 pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) over Symbicort Turbuhaler in terms of pulmonary function, as well as to assess its safety.

Clinical Study Identifier: NCT03197818

Contact Investigators or Research Sites near you

Start Over

Chiesi Clinical Trial Info

Chiesi Clinical Trial Site 158002
Yongkang, Taiwan
  Connect »